Tags : Neuromyelitis

Roche Reports Results of Satralizumab in P-III SAkuraSky Study to

Shots: The P-III SAkuraSky study involves assessing of satralizumab (120mg, SC) + baseline immunosuppressant therapy vs PBO + baseline immunosuppressant therapy in ratio (1:1) in 83 patients with NMOSD P-III study results: relapse-free patients @ 48, 96 and 144wks. (89%, 78%, 74% vs 66%, 59%, 49%), Experienced PDR (20% vs 43%); AQP4-IgG seropositive & seronegative […]Read More